Table 3:

Univariable and multivariable analyses of parameters influencing OS

Parameters Univariable
Multivariable
HR95% CIPHR95% CIP
Age (ref. <70 years)
 ≥701.140.71–1.760.563
Gender (ref. male)
 Female0.820.54–1.200.300
Histological type (ref. LG-TC)
 HG-TC1.350.65–2.490.391
 NOS-TC1.200.73–1.880.446
Resection status (ref. R2 non-resection)
 R00.160.09–0.28<0.0010.270.15–0.48<0.001
 R10.420.23–0.77<0.0010.400.22–0.740.004
 R2 sub-total0.430.22–0.81<0.0010.380.20–0.720.003
Pathological Masaoka stage (ref. I–II)
 II3.721.94–7.88<0.0012.971.45–6.100.003
 IV7.814.16–16.3<0.0014.962.33–10.5<0.001
Preoperative CT (ref. no)
 Yes1.961.28–2.920.0021.270.81–1.980.295
Postoperative RT (ref. no)
 Yes1.180.81–1.720.3771.050.72–1.540.793
Parameters Univariable
Multivariable
HR95% CIPHR95% CIP
Age (ref. <70 years)
 ≥701.140.71–1.760.563
Gender (ref. male)
 Female0.820.54–1.200.300
Histological type (ref. LG-TC)
 HG-TC1.350.65–2.490.391
 NOS-TC1.200.73–1.880.446
Resection status (ref. R2 non-resection)
 R00.160.09–0.28<0.0010.270.15–0.48<0.001
 R10.420.23–0.77<0.0010.400.22–0.740.004
 R2 sub-total0.430.22–0.81<0.0010.380.20–0.720.003
Pathological Masaoka stage (ref. I–II)
 II3.721.94–7.88<0.0012.971.45–6.100.003
 IV7.814.16–16.3<0.0014.962.33–10.5<0.001
Preoperative CT (ref. no)
 Yes1.961.28–2.920.0021.270.81–1.980.295
Postoperative RT (ref. no)
 Yes1.180.81–1.720.3771.050.72–1.540.793

OS: overall survival; HR: hazard ratio; CI: confidence interval; LG-TC: low-grade thymic carcinoma; HG-TC: high-grade thymic carcinoma; NOS-TC: thymic carcinoma, not otherwise specified; CT: chemotherapy; RT: radiotherapy.

Table 3:

Univariable and multivariable analyses of parameters influencing OS

Parameters Univariable
Multivariable
HR95% CIPHR95% CIP
Age (ref. <70 years)
 ≥701.140.71–1.760.563
Gender (ref. male)
 Female0.820.54–1.200.300
Histological type (ref. LG-TC)
 HG-TC1.350.65–2.490.391
 NOS-TC1.200.73–1.880.446
Resection status (ref. R2 non-resection)
 R00.160.09–0.28<0.0010.270.15–0.48<0.001
 R10.420.23–0.77<0.0010.400.22–0.740.004
 R2 sub-total0.430.22–0.81<0.0010.380.20–0.720.003
Pathological Masaoka stage (ref. I–II)
 II3.721.94–7.88<0.0012.971.45–6.100.003
 IV7.814.16–16.3<0.0014.962.33–10.5<0.001
Preoperative CT (ref. no)
 Yes1.961.28–2.920.0021.270.81–1.980.295
Postoperative RT (ref. no)
 Yes1.180.81–1.720.3771.050.72–1.540.793
Parameters Univariable
Multivariable
HR95% CIPHR95% CIP
Age (ref. <70 years)
 ≥701.140.71–1.760.563
Gender (ref. male)
 Female0.820.54–1.200.300
Histological type (ref. LG-TC)
 HG-TC1.350.65–2.490.391
 NOS-TC1.200.73–1.880.446
Resection status (ref. R2 non-resection)
 R00.160.09–0.28<0.0010.270.15–0.48<0.001
 R10.420.23–0.77<0.0010.400.22–0.740.004
 R2 sub-total0.430.22–0.81<0.0010.380.20–0.720.003
Pathological Masaoka stage (ref. I–II)
 II3.721.94–7.88<0.0012.971.45–6.100.003
 IV7.814.16–16.3<0.0014.962.33–10.5<0.001
Preoperative CT (ref. no)
 Yes1.961.28–2.920.0021.270.81–1.980.295
Postoperative RT (ref. no)
 Yes1.180.81–1.720.3771.050.72–1.540.793

OS: overall survival; HR: hazard ratio; CI: confidence interval; LG-TC: low-grade thymic carcinoma; HG-TC: high-grade thymic carcinoma; NOS-TC: thymic carcinoma, not otherwise specified; CT: chemotherapy; RT: radiotherapy.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close